• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » EC Details What to Include in Protocol Synopses Submitted with Trial Applications

EC Details What to Include in Protocol Synopses Submitted with Trial Applications

October 25, 2021

The European Commission (EC) has issued an updated Q&A outlining what information sponsors should provide in the protocol synopses they must submit with their clinical trial applications under the upcoming Clinical Trials Regulation (CTR) set for launch in January 2022.

The synopsis, which should be two pages long at most, should be understandable to the average person and can be included within the protocol itself or attached as a separate document if it’s submitted in different languages.

The Q&A explains that the EC expects a synopsis to include:

  • The EU trial number and full title of the trial;
  • Rationale (the background and hypothesis of the trial);
  • Objective (the main and secondary objectives of the trial);
  • Main and secondary trial endpoints (a description of the primary and secondary trial endpoints and when they are assessed);
  • Trial design (the design and expected duration of the trial for individual subjects);
  • Trial population (a description of the trial population that indicates the main inclusion criteria being used, as well as the exclusion criteria in place to protect subjects);
  • Interventions (a description of the interventions and treatment duration, as well as background treatment, if applicable); and
  • Ethical considerations for the trial (including expected benefit, burdens and risks to trial participants).

It also includes a new Q&A section clarifying how sponsors should report their anticipated submission date for annual safety reports (ASRs).

Further updates of the Q&A, which is still in draft form, will be issued, the commission noted.

Read the full revised Q&A here: https://bit.ly/3E6ScEf.

 

To view more CenterWatch Weekly stories, click here.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing